The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk

Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled down on transcatheter valve replacement with $1.15 billion in TAVR sales, up 12.4%, while Boston Scientific exited TAVR entirely and leaned into its diversified cardiovascular platform.

One Specialist, One Diversifier

Edwards delivered $1.55 billion in Q3 2025 revenue, beating estimates by $50 million. The company’s TAVR franchise continues dominating a market Edwards helped create. CEO Bernard Zovighian raised 2026 guidance to the high end of 9-10% sales growth. The SAPIEN M3 achieved its primary endpoint in the ENCIRCLE trial for mitral replacement, expanding Edwards’ reach beyond aortic valves. The company grew its transcatheter mitral and tricuspid therapies segment 59.3% to $145.2 million.

Boston Scientific took a different path. The company posted $5.29 billion in Q4 2025 revenue, up 15.9%, but discontinued its ACURATE neo2 and Prime Aortic Valve Systems, eliminating roughly $50 million per quarter in TAVR sales. CEO Mike Mahoney emphasized category leadership across a broader cardiovascular portfolio. The FARAPOINT PFA Catheter received FDA approval, and the company launched the SEISMIQ Intravascular Lithotripsy System. Boston Scientific’s cardiovascular segment grew 18.2%, driven by electrophysiology and interventional cardiology.

Where the Paths Diverge

Edwards is betting transcatheter valve replacement will continue expanding as new ESC/EACTS guidelines simplify AS care pathways and drive earlier intervention. The company’s $2.1 billion share buyback authorization and consistent gross margins above 78% reflect confidence in its premium positioning.

Boston Scientific chose scale over specialization. The company’s acquisition of Nalu Medical and Valencia Technologies expanded its neuromodulation and pelvic health portfolios. The FARAPULSE PFA System received PMDA approval in Japan, opening a major market for its electrophysiology franchise. Boston Scientific’s operating income surged 384.5% to $2.85 billion, demonstrating the profitability of its category leadership model.

Which Strategy Holds Up Through 2026?

Edwards faces a narrower path. If TAVR adoption slows or competition intensifies, the company has limited diversification. Boston Scientific’s exit from TAVR suggests it saw margin pressure coming. Edwards’ four consecutive quarters of earnings beats in 2025 validate its execution, but the company’s 34x trailing P/E ratio leaves little room for disappointment.

Boston Scientific’s broader portfolio offers more resilience. The company’s PEG ratio of 0.737 suggests the market is undervaluing its growth. Its 95.3% institutional ownership reflects confidence in the diversification strategy.

Strategic Positioning Through 2026

Edwards offers concentrated exposure to transcatheter valve replacement with its 23.3% profit margin and analyst target of $96.98. The company’s specialized focus delivers premium margins but creates concentration risk if TAVR adoption slows. Boston Scientific’s diversified cardiovascular platform spreads risk across multiple growth categories including PFA, lithotripsy, and neuromodulation. The company’s PEG ratio of 0.737 and willingness to exit TAVR demonstrates disciplined capital allocation. Each approach carries distinct risk-reward profiles depending on market conditions and competitive dynamics.